155 related articles for article (PubMed ID: 32998637)
1. HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk.
Khawaja AA; Taylor KA; Lovell AO; Nelson M; Gazzard B; Boffito M; Emerson M
Circ Res; 2020 Nov; 127(11):1365-1380. PubMed ID: 32998637
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.
Taylor KA; Smyth E; Rauzi F; Cerrone M; Khawaja AA; Gazzard B; Nelson M; Boffito M; Emerson M
Br J Pharmacol; 2019 Apr; 176(7):879-889. PubMed ID: 30681136
[TBL] [Abstract][Full Text] [Related]
3. Human platelets express functional ectonucleotidases that restrict platelet activation signaling.
Chaurasia SN; Kushwaha G; Pandey A; Dash D
Biochem Biophys Res Commun; 2020 Jun; 527(1):104-109. PubMed ID: 32446352
[TBL] [Abstract][Full Text] [Related]
4. Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: A step from inflammation to thrombosis.
Alvarez A; Rios-Navarro C; Blanch-Ruiz MA; Collado-Diaz V; Andujar I; Martinez-Cuesta MA; Orden S; Esplugues JV
Antiviral Res; 2017 May; 141():179-185. PubMed ID: 28263802
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
De Pablo C; Orden S; Calatayud S; Martí-Cabrera M; Esplugues JV; Alvarez A
Antivir Ther; 2012; 17(8):1615-9. PubMed ID: 22954798
[TBL] [Abstract][Full Text] [Related]
7. Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions.
O'Halloran JA; Dunne E; Tinago W; Denieffe S; Kenny D; Mallon PWG
AIDS; 2018 Apr; 32(7):861-866. PubMed ID: 29438200
[TBL] [Abstract][Full Text] [Related]
8. The volatile anesthetic isoflurane increases endothelial adenosine generation via microparticle ecto-5'-nucleotidase (CD73) release.
Kim M; Ham A; Kim KY; Brown KM; Lee HT
PLoS One; 2014; 9(6):e99950. PubMed ID: 24945528
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
10. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
[No Abstract] [Full Text] [Related]
11. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
[TBL] [Abstract][Full Text] [Related]
12. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
Falcinelli E; Francisci D; Belfiori B; Petito E; Guglielmini G; Malincarne L; Mezzasoma A; Sebastiano M; Conti V; Giannini S; Bonora S; Baldelli F; Gresele P
Thromb Haemost; 2013 Aug; 110(2):349-57. PubMed ID: 23703656
[TBL] [Abstract][Full Text] [Related]
13. Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome.
Fan GQ; Qin RR; Li YH; Song DJ; Chen TS; Zhang W; Zhong M; Zhang Y; Xing YQ; Wang ZH
Oncotarget; 2016 Dec; 7(50):83231-83240. PubMed ID: 27825126
[TBL] [Abstract][Full Text] [Related]
14. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
[TBL] [Abstract][Full Text] [Related]
15. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
17. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism.
Jansen F; Yang X; Baumann K; Przybilla D; Schmitz T; Flender A; Paul K; Alhusseiny A; Nickenig G; Werner N
J Cell Mol Med; 2015 Sep; 19(9):2202-14. PubMed ID: 26081516
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide fumarate for the treatment of HIV infection.
Sampath R; Zeuli J; Rizza S; Temesgen Z
Drugs Today (Barc); 2016 Nov; 52(11):617-625. PubMed ID: 28112280
[TBL] [Abstract][Full Text] [Related]
20. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension.
Visovatti SH; Hyman MC; Bouis D; Neubig R; McLaughlin VV; Pinsky DJ
PLoS One; 2012; 7(7):e40829. PubMed ID: 22792409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
